Nonmelanoma skin cancer chemoprevention

Dermatologic Surgery

Volumn 37, Issue 11, 2011, Pages 1566-1578

  Prado, Renata ^a   Francis, Shayla O ^a   Mason, Mariah N ^a   Wing, Gregory ^a   Gamble, Ryan G ^a   Dellavalle, Robert ^a,b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c Global Health and Health Disparities   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; ANTHOCYANIN; CAFFEIC ACID; CALCIUM; CATECHIN; CELECOXIB; DEOXYRIBONUCLEASE (PYRIMIDINE DIMER); DICLOFENAC; EFLORNITHINE; EPIGALLOCATECHIN GALLATE; ETRETIN; FLAVANOL DERIVATIVE; FLAVANONE; FLAVONE; FLAVONOID; FLUOROURACIL; IMIQUIMOD; LIGNAN; NONSTEROID ANTIINFLAMMATORY AGENT; PERILLYL ALCOHOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; POLYPHENOL; PROANTHOCYANIDIN; PROCYANIDIN; RETINOID; TANNIN; UNINDEXED DRUG; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ACTINIC KERATOSIS; ARTICLE; BASAL CELL CARCINOMA; BONE DISEASE; BRAIN PSEUDOTUMOR; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEMINERALIZATION; DIETARY INTAKE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; HAIR LOSS; HUMAN; INTERVERTEBRAL DISK; LIGAMENT CALCINOSIS; LIVER TOXICITY; MELANOMA; NONHUMAN; NONMELANOMA SKIN CANCER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; ULTRAVIOLET B RADIATION;

ACITRETIN; AMINOLEVULINIC ACID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DEOXYRIBONUCLEASE (PYRIMIDINE DIMER); EFLORNITHINE; HUMANS; MONOTERPENES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; POLYPHENOLS; RETINOIDS; SKIN NEOPLASMS; VIRAL PROTEINS;

EID: 80755175847     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2011.02108.x     Document Type: Article

References (140)

1. Trakatelli M, Ulrich C, del Marmol V, Euvrad S, et al,. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007; 156 (Suppl 3): 1-7. (Pubitemid 46646534)
2. Einspahr JG, Stratton SP, Bowden GT, Alberts DS,. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 2002; 41: 269-85. (Pubitemid 34203664)
3. Dragnev KH, Rigas JR, Dmitrovsky E., The retinoids and cancer prevention mechanisms. Oncologist 2000; 5: 361-8.
4. Armstrong BK, Kricker A., The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001; 63: 8-18. (Pubitemid 33040718)
5. Wright TI, Spencer JM, Flowers FP., Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol 2006; 54: 933-46; quiz 47-50.
6. Hannuksela-Svahn A, Pukkala E, Karvonen J., Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol 1999; 135: 781-6. (Pubitemid 29330800)
7. Ridky TW., Nonmelanoma skin cancer. J Am Acad Dermatol 2007; 57: 484-501. (Pubitemid 47239135)
8. London NJ, Farmery SM, Will EJ, Davison AM, et al,. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403-6.
9. Euvrard S, Kanitakis J, Claudy A., Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-91. (Pubitemid 36459475)
10. Berg D, Otley CC., Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47: 1-17; quiz 18-20.
11. Sporn MB., Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976; 36: 2699-702.
12. Lens M, Medenica L., Systemic retinoids in chemoprevention of non-melanoma skin cancer. Expert Opin Pharmacother 2008; 9: 1363-74. (Pubitemid 351877519)
13. Patton TJ, Zirwas MJ, Wolverton SE., Systemic Retinoids. 2nd ed. Philadelphia: Elsevier; 2007.
14. Altucci L, Gronemeyer H., The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1: 181-93. (Pubitemid 33741893)
15. Levine N., Role of retinoids in skin cancer treatment and prevention. J Am Acad Dermatol 1998; 39: S62-6. (Pubitemid 28367289)
16. Mrass P, Rendl M, Mildner M, Gruber F, et al,. Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. Cancer Res 2004; 64: 6542-8. (Pubitemid 39297912)
17. Spinella MJ, Freemantle SJ, Sekula D, Chang JH, et al,. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem 1999; 274: 22013-8.
18. Langenfeld J, Kiyokawa H, Sekula D, Boyle J, et al,. Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci U S A 1997; 94: 12070-4. (Pubitemid 27467844)
19. Rendl M, Ban J, Mrass P, Mayer C, et al,. Caspase-14 expression by epidermal keratinocytes is regulated by retinoids in a differentiation- associated manner. J Invest Dermatol 2002; 119: 1150-5. (Pubitemid 35430492)
20. Fanjul A, Dawson MI, Hobbs PD, Jong L, et al,. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 1994; 372: 107-11. (Pubitemid 24339493)
21. Cheepala SB, Yin W, Syed Z, Gill JN, et al,. Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer 2009; 8: 27.
22. Moon TE, Levine N, Cartmel B, et al,. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997; 6: 949-56. (Pubitemid 27481644)
23. Kraemer KH, DiGiovanna JJ, Peck GL., Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 1992; 19: 715-8. (Pubitemid 23119632)
24. Bavinck JN, Tieben LM, Van der Woude FJ, Tegzess AM, et al,. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 1933-8.
25. Tangrea JA, Edwards BK, Taylor PR, Hartman AM, et al,. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst 1992; 84: 328-32.
26. McKenna DB, Murphy GM., Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999; 140: 656-60. (Pubitemid 29191384)
27. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, et al,. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633-7.
28. Levine N, Moon TE, Cartmel B, Bangert JL, et al,. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997; 6: 957-61. (Pubitemid 27481645)
29. Nijsten TE, Stern RS., Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003; 49: 644-50. (Pubitemid 37210277)
30. George R, Weightman W, Russ GR, Bannister KM, et al,. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002; 43: 269-73. (Pubitemid 35365416)
31. de Sevaux RG, Smit JV, de Jong EM, van de Kerkhof PC, et al,. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 2003; 49: 407-12. (Pubitemid 37051901)
32. Otley CC, Stasko T, Tope WD, Lebwohl M, et al,. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006; 32: 562-8.
33. Varma S, Wilson H, Kurwa HA, Gambles B, et al,. Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol 2001; 144: 567-74. (Pubitemid 32232013)
34. Markham T, Collins P., Topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratoses. Br J Dermatol 2001; 145: 502-4. (Pubitemid 32953713)
35. Alexiades-Armenakas MR, Geronemus RG., Laser-mediated photodynamic therapy of actinic keratoses. Arch Dermatol 2003; 139: 1313-20. (Pubitemid 37248282)
36. Alexiades-Armenakas MR, Geronemus RG., Laser-mediated photodynamic therapy of actinic cheilitis. J Drugs Dermatol 2004; 3: 548-51.
37. Alexiades-Armenakas M., Aminolevulinic acid photodynamic therapy for actinic keratoses/actinic cheilitis/acne: vascular lasers. Dermatol Clin 2007; 25: 25-33. (Pubitemid 44780058)
38. de Graaf YG, Kennedy C, Wolterbeek R, Willemze R, et al,. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: Results: of a randomized-controlled trial. J Invest Dermatol 2006; 126: 569-74. (Pubitemid 43255643)
39. Apalla Z, Sotiriou E, Chovarda E, Lefaki I, et al,. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol 162: 171-5.
40. Fritsch C, Homey B, Stahl W, Lehmann P, et al,. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol 1998; 68: 218-21. (Pubitemid 128472013)
41. Fritsch C, Lang K, Neuse W, Ruzicka T, et al,. Photodynamic diagnosis and therapy in dermatology. Skin Pharmacol Appl Skin Physiol 1998; 11: 358-73. (Pubitemid 29250980)
42. Caty V, Liu Y, Viau G, Bissonnette R,. Multiple large surface photodynamic therapy sessions with topical methylaminolaevulinate in PTCH heterozygous mice. Br J Dermatol 2006; 154: 740-2. (Pubitemid 43374102)
43. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA,. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006; 86: 25-8. (Pubitemid 46939784)
44. Kleinpenning MM, van de Kerkhof PC, Gerritsen RM., The clinical efficacy of topical methyl-aminolevulinate photodynamic therapy in moderate to severe actinic keratoses of the face and scalp. J Dermatol Treat 21: 252-7.
45. Zane C, Capezzera R, Sala R, Venturini M, et al,. Clinical and echographic analysis of photodynamic therapy using methylaminolevulinate as sensitizer in the treatment of photodamaged facial skin. Lasers Surg Med 2007; 39: 203-9. (Pubitemid 46623029)
46. Marks F, Furstenberger G, Neufang G, Müller-Decker K,. Mouse skin as a model for cancer chemoprevention by nonsteroidal anti-inflammatory drugs. Recent Results: Cancer Res 2003; 163: 46-57; discussion 264-6.
47. Pentland AP, Schoggins JW, Scott GA, Khan KN, et al,. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999; 20: 1939-44. (Pubitemid 29476120)
48. An KP, Athar M, Tang X, Katiyar SK, et al,. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 2002; 76: 73-80.
49. Higashi Y, Kanekura T, Kanzaki T., Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000; 86: 667-71. (Pubitemid 30249877)
50. Muller-Decker K, Reinerth G, Krieg P, Zimmermann R, et al,. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin. Int J Cancer 1999; 82: 648-56. (Pubitemid 29356962)
51. Tiano HF, Loftin CD, Akunda J, Lee CA, et al,. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002; 62: 3395-401. (Pubitemid 34651385)
52. Grau MV, Baron JA, Langholz B, Kargas M, et al,. Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer 2006; 119: 682-6. (Pubitemid 43955724)
53. Grewe M, Trefzer U, Ballhorn A, Gyufko K, et al,. Analysis of the mechanism of ultraviolet (UV) B radiation-induced prostaglandin E2 synthesis by human epidermoid carcinoma cells. J Invest Dermatol 1993; 101: 528-31. (Pubitemid 23285847)
54. Lozano Y, Taitz A, Petruzzelli GJ, Djordievic A, et al,. Prostaglandin E2-protein kinase A signaling and protein phosphatases-1 and -2A regulate human head and neck squamous cell carcinoma motility, adherence, and cytoskeletal organization. Prostaglandins 1996; 51: 35-48.
55. Bowden GT., Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nat Rev Cancer 2004; 4: 23-35. (Pubitemid 38082151)
56. Buckman SY, Gresham A, Hale P, Hruza G, et al,. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19: 723-9. (Pubitemid 28376760)
57. Mittal A, Elmets CA, Katiyar SK., Dietary feeding of proanthocyanidins from grape seeds prevents photocarcinogenesis in SKH-1 hairless mice: relationship to decreased fat and lipid peroxidation. Carcinogenesis 2003; 24: 1379-88. (Pubitemid 37038827)
58. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, et al,. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-6.
59. Thun MJ, Namboodiri MM, Heath CW Jr., Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6.
60. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, et al,. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-7. (Pubitemid 23097110)
61. Khuder SA, Mutgi AB., Breast cancer and NSAID use: a meta-analysis. Br J Cancer 2001; 84: 1188-92. (Pubitemid 32511336)
62. Norrish AE, Jackson RT, McRae CU., Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998; 77: 511-5. (Pubitemid 28340895)
63. Muscat JE, Chen SQ, Richie JP Jr., Altorki NK, et al,. Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer 2003; 97: 1732-6. (Pubitemid 36350716)
64. Ma WY, Huang C, Dong Z., Inhibition of ultraviolet C irradiation-induced AP-1 activity by aspirin is through inhibition of JNKs but not erks or P38 MAP kinase. Int J Oncol 1998; 12: 565-8. (Pubitemid 28097283)
65. Huang C, Ma WY, Hanenberger D, Bowden GT, et al,. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem 1997; 272: 26325-31. (Pubitemid 27458846)
66. Bair WB III, Hart N, Einspahr J, Liu GE, et al,. Inhibitory effects of sodium salicylate and acetylsalicylic acid on UVB-induced mouse skin carcinogenesis. Cancer Epidemiol Biomarkers Prev 2002; 11: 1645-52. (Pubitemid 36020019)
67. Fischer SM, Lo HH, Gordon GB, Seibert K, et al,. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinogen 1999; 25: 231-40. (Pubitemid 29372908)
68. Kapadia GJ, Azuine MA, Shigeta Y, Suzuki N, et al,. Chemopreventive activities of etodolac and oxyphenbutazone against mouse skin carcinogenesis. Bioorg Med Chem Lett 20: 2546-8.
69. Fecker LF, Stockfleth E, Braun FK, Rodust PM, et al,. Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP. J Invest Dermatol 2010; 130: 2098-109.
70. Wilgus TA, Ross MS, Parrett ML, Oberyszyn TM, et al,. Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostaglandins Other Lipid Mediat 2000; 62: 367-84.
71. Nelson C, Rigel D, Smith S, Swanson N, et al,. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004; 3: 401-7.
72. Wolf JE Jr., Taylor JR, Tschen E, Kang S,. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-13. (Pubitemid 34023642)
73. Sorensen HT, Friis S, Norgard B, et al,. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003; 88: 1687-92. (Pubitemid 36760410)
74. Friis S, Sorensen HT, McLaughlin JK, Mellemkjaer L, et al,. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003; 88: 684-8. (Pubitemid 36411444)
75. Asgari MM, Chren MM, Warton EM, Friedman GD, et al,. Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma. Arch Dermatol 146: 388-95.
76. Butler GJ, Neale R, Green AC, Pandeya N, et al,. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol 2005; 53: 966-72. (Pubitemid 41677321)
77. Elmets CA, Viner JL, Pentland AP, Cantrell W, et al,. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 102: 1835-44.
78. Meyskens FL Jr., McLaren CE., Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? J Natl Cancer Inst 102: 1815-7.
79. Gilmour SK., Polyamines and nonmelanoma skin cancer. Toxicol Appl Pharmacol 2007; 224: 249-56. (Pubitemid 47575671)
80. Verma AK, Lowe NJ, Boutwell RK., Induction of mouse epidermal ornithine decarboxylase activity and DNA synthesis by ultraviolet light. Cancer Res 1979; 39: 1035-40. (Pubitemid 9135130)
81. Ahmad N, Gilliam AC, Katiyar SK, O'Brien TG, et al,. A definitive role of ornithine decarboxylase in photocarcinogenesis. Am J Pathol 2001; 159: 885-92. (Pubitemid 32847179)
82. O'Brien TG., The induction of ornithine decarboxylase as an early, possibly obligatory, event in mouse skin carcinogenesis. Cancer Res 1976; 36: 2644-53.
83. Gilmour SK, Verma AK, Madara T, O'Brien TG,. Regulation of ornithine decarboxylase gene expression in mouse epidermis and epidermal tumors during two-stage tumorigenesis. Cancer Res 1987; 47: 1221-5. (Pubitemid 17023184)
84. Rebel H, van Steeg H, Beems RB, Schouten R, et al,. Suppression of UV carcinogenesis by difluoromethylornithine in nucleotide excision repair-deficient Xpa knockout mice. Cancer Res 2002; 62: 1338-42. (Pubitemid 34407789)
85. Takigawa M, Verma AK, Simsiman RC, Boutwell RK,. Polyamine biosynthesis and skin tumor promotion: inhibition of 12-O-tetradecanoylphorbol-13-acetate- promoted mouse skin tumor formation by the irreversible inhibitor of ornithine decarboxylase alpha-difluoromethylornithine. Biochem Biophys Res Commun 1982; 105: 969-76. (Pubitemid 13219426)
86. Takigawa M, Verma AK, Simsiman RC, Boutwell RK,. Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine biosynthesis by alpha-difluoromethylornithine. Cancer Res 1983; 43: 3732-8. (Pubitemid 13028510)
87. Weeks CE, Herrmann AL, Nelson FR, Slaga TJ,. alpha- Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc Natl Acad Sci U S A 1982; 79: 6028-32.
88. Fischer SM, Lee M, Lubet RA., Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice. Carcinogenesis 2001; 22: 83-8. (Pubitemid 32098148)
89. Lan L, Trempus C, Gilmour SK., Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice. Cancer Res 2000; 60: 5696-703.
90. Arbeit JM, Riley RR, Huey B, Porter C, et al,. Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice. Cancer Res 1999; 59: 3610-20. (Pubitemid 29381862)
91. Chen Y, Weeks RS, Burns MR, Boorman DW, et al,. Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma. Int J Cancer 2006; 118: 2344-9.
92. Carbone PP, Pirsch JD, Thomas JP, Douglas JA, et al,. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. Cancer Epidemiol Biomarkers Prev 2001; 10: 657-61. (Pubitemid 32703200)
93. Alberts DS, Dorr RT, Einspahr JG, Aickin M, et al,. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev 2000; 9: 1281-6. (Pubitemid 32044795)
94. Einspahr JG, Nelson MA, Saboda K, Warneke J, et al,. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. Clin Cancer Res 2002; 8: 149-55. (Pubitemid 34101471)
95. Bailey HH, Kim K, Verma AK, et al,. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}- difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res (Phila Pa) 3: 35-47.
96. Tang X, Kim AL, Feith DJ, Pegg AE, et al,. Ornithine decarboxylase is a target for chemoprevention of basal and squamous cell carcinomas in Ptch1+/- mice. J Clin Invest 2004; 113: 867-75. (Pubitemid 38544145)
97. Tanaka K, Sekiguchi M, Okada Y., Restoration of ultraviolet-induced unscheduled DNA synthesis of xeroderma pigmentosum cells by the concomitant treatment with bacteriophage T4 endonuclease V and HVJ (Sendai virus). Proc Natl Acad Sci U S A 1975; 72: 4071-5.
98. Cafardi JA, Elmets CA., T4 endonuclease V: review and application to dermatology. Expert Opin Biol Ther 2008; 8: 829-38. (Pubitemid 351860212)
99. Wolf P, Maier H, Mullegger RR, Chadwick CA, et al,. Topical treatment with liposomes containing T4 endonuclease V protects human skin in vivo from ultraviolet-induced upregulation of interleukin-10 and tumor necrosis factor-alpha. J Invest Dermatol 2000; 114: 149-56. (Pubitemid 30195988)
100. Yarosh D, Bucana C, Cox P, Alas L, et al,. Localization of liposomes containing a DNA repair enzyme in murine skin. J Invest Dermatol 1994; 103: 461-8. (Pubitemid 24314828)
101. Morikawa K, Shirakawa M., Three-dimensional structural views of damaged-DNA recognition: T4 endonuclease V, E. coli Vsr protein, and human nucleotide excision repair factor XPA. Mutat Res 2000; 460: 257-75. (Pubitemid 30628595)
102. Yarosh D, Alas LG, Yee V, Obseryszyn A, et al,. Pyrimidine dimer removal enhanced by DNA repair liposomes reduces the incidence of UV skin cancer in mice. Cancer Res 1992; 52: 4227-31.
103. Bito T, Ueda M, Nagano T, Fujii S, et al,. Reduction of ultraviolet-induced skin cancer in mice by topical application of DNA excision repair enzymes. Photodermatol Photoimmunol Photomed 1995; 11: 9-13.
104. Yarosh D, Klein J, O'Connor A, Hawk J, et al,. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet 2001; 357: 926-9. (Pubitemid 32247282)
105. Elmets CA., A Phase IIb randomized, double-blind, placebo-controlled clinical trial of topical bacteriophage t4 endonuclease v in renal allograft recipients with a history of non-melanoma skin cancer. ClinicalTrials. gov Identifier: NCT00089180. Available from: Accessed June 18, 2010.
106. Yarosh DB., A randomized, double-blind, multicenter clinical study to test the safety and efficacy of T4N5 liposome lotion on patients with xeroderma pigmentosum in the protection against actinic keratosis. ClinicalTrials.gov Identifier: NCT00002811. Available from: Accessed June 18, 2010.
107. Nichols JA, Katiyar SK., Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res 302: 71-83.
108. Katiyar SK, Agarwal R, Wood GS, Mukhtar H,. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-caused tumor promotion in 7,12-dimethylbenz[a]anthracene-initiated SENCAR mouse skin by a polyphenolic fraction isolated from green tea. Cancer Res 1992; 52: 6890-7. (Pubitemid 23006295)
109. Agarwal R, Katiyar SK, Khan SG, Mukhtar H,. Protection against ultraviolet B radiation-induced effects in the skin of SKH-1 hairless mice by a polyphenolic fraction isolated from green tea. Photochem Photobiol 1993; 58: 695-700. (Pubitemid 2028260)
110. Barthelman M, Bair WB 3rd, Stickland KK, Chen W, et al,. (-)-Epigallocatechin-3-gallate inhibition of ultraviolet B-induced AP-1 activity. Carcinogenesis 1998; 19: 2201-4. (Pubitemid 29010263)
111. Liang YC, Lin-shiau SY, Chen CF, Lin JK,. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem 1997; 67: 55-65.
112. Katiyar SK, Vaid M, van Steeg H, Meeran SM,. Green tea polyphenols prevent UV-induced immunosuppression by rapid repair of DNA damage and enhancement of nucleotide excision repair genes. Cancer Prev Res (Phila Pa) 3: 179-89.
113. Katiyar SK., Skin photoprotection by green tea: antioxidant and immunomodulatory effects. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3: 234-42.
114. Lluria-Prevatt M, Morreale J, Gregus J, Alberts DS, et al,. Effects of perillyl alcohol on melanoma in the TPras mouse model. Cancer Epidemiol Biomarkers Prev 2002; 11: 573-9. (Pubitemid 34615165)
115. Barthelman M, Chen W, Gensler HL, Huang C, et al,. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res 1998; 58: 711-6. (Pubitemid 28099482)
116. Hakim IA, Harris RB, Ritenbaugh C., Citrus peel use is associated with reduced risk of squamous cell carcinoma of the skin. Nutr Cancer 2000; 37: 161-8.
117. Stratton SP, Saboda KL, Myrdal PB, Gupta A, et al,. Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer. Nutr Cancer 2008; 60: 325-30. (Pubitemid 351601364)
118. Stratton SP, Alberts DS, Einspahr JG, Sagerman PM, et al,. A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer. Cancer Prev Res (Phila Pa) 3: 160-9.
119. Thuillier P, Anchiraico GJ, Nickel KP, Maldve RE, et al,. Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion. Mol Carcinog 2000; 29: 134-42.
120. He G, Muga S, Thuillier P, Lubert RA, et al,. The effect of PPARgamma ligands on UV- or chemically-induced carcinogenesis in mouse skin. Mol Carcinog 2005; 43: 198-206. (Pubitemid 41134427)
121. Bility MT, Zhu B, Kang BH, Gonzalez FJ, et al,. Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis. Toxicol Sci 113: 27-36.
122. Sertznig P, Seifert M, Tilgen W, Reichrath J,. Peroxisome proliferator-activated receptor (PPAR) and vitamin D receptor (VDR) signaling pathways in melanoma cells: promising new therapeutic targets? J Steroid Biochem Mol Biol 121: 383-6.
123. Deeb KK, Trump DL, Johnson CS., Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7: 684-700. (Pubitemid 47327412)
124. Gandini S, Raimondi S, Gnagnarella P, Dore JF, et al,. Vitamin D and skin cancer: a meta-analysis. Eur J Cancer 2009; 45: 634-41.
125. Garland CF, Garland FC, Gorham ED, Lipkin M, et al,. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96: 252-61. (Pubitemid 43167123)
126. Oberyszyn TM., Non-melanoma skin cancer: importance of gender, immunosuppressive status and vitamin D. Cancer Lett 2008; 261: 127-36.
127. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, et al,. Vitamin D and calcium supplementation reduces cancer risk: Results: of a randomized trial. Am J Clin Nutr 2007; 85: 1586-91. (Pubitemid 46890428)
128. Tang JY, Parimi N, Wu A, Boscardin WJ, et al,. Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. Cancer Causes Control 2010; 21: 387-91.
129. Lowry F., Calcium and vitamin D may reduce melanoma risk in high-risk women. In: Medscape Medical News; 2011.
130. Black HS, Lenger W, Phelps AW, Thornby JI,. Influence of dietary lipid upon ultraviolet light-carcinogenesis. J Environ Pathol Toxicol Oncol 1984; 5: 271-82. (Pubitemid 15162427)
131. Black HS., Influence of dietary factors on actinically-induced skin cancer. Mutat Res 1998; 422: 185-90. (Pubitemid 28515628)
132. Yentzer B, Hick J, Williams L, Inabinet R, et al,. Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch Dermatol 2009; 145: 203-5.
133. Loven K, Stein L, Furst K, Levy S,. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24: 990-1000. (Pubitemid 34734743)
134. Weiss J, Menter A, Hevia O, Ling M, et al,. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002; 70: 22-9.
135. Korman N, Moy R, Ling M, Matheson R, et al,. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: Results: of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141: 467-73. (Pubitemid 40547405)
136. Patel GK, Goodwin R, Chawla M, Laidler P, et al,. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006; 54: 1025-32.
137. Zeichner JA, Stern DW, Uliasz A, Itenberg S, et al,. Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. J Am Acad Dermatol 2009; 60: 59-62.
138. Love WE, Bernhard JD, Bordeaux JS., Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009; 145: 1431-8.
139. Shumack S, Robinson J, Kossard S, Golitz L, et al,. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002; 138: 1165-71. (Pubitemid 35025688)
140. Boukamp P., Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005; 26: 1657-67. (Pubitemid 41487981)